GrifolsMEX:GRFP N 83 Net Margin % is 4.29% as of Mar. 2026, which is 49% below its 10-year median of 8.46. GuruFocus rates MEX:GRFP N with a GF Score™ of 83/100 and a GF Value™ of MXN154.24. The stock has 6 warning signs investors should review. Among 956 Drug Manufacturers companies, Grifols ranks better than 50% on this metric.
Net margin is calculated as Net Income divided by its Revenue. Grifols's Net Income for the
three
months ended in Mar. 2026 was MXN1,522 Mil. Grifols's Revenue for the
three
months ended in Mar. 2026 was MXN35,440 Mil. Therefore, Grifols's net margin for the quarter that ended in Mar. 2026 was 4.29%.
The historical rank and industry rank for Grifols's Net Margin % or its related term are showing as below:
MEX:GRFP N'
s Net Margin % Range Over the Past 10 Years
Min: 0.64 Med: 8.46 Max: 15.35
Current: 5.58
MEX:GRFP N's Net Margin % is ranked better than 50% of 956
companies
in the Drug Manufacturers industry
Industry Median: 5.56
vs MEX:GRFP N: 5.58
Grifols (MEX:GRFP N) Net Margin % Explanation
Although Net Income and Earnings-per-Share (EPS) are the most widely used parameter in measuring a company's profitability and valuation, it is the least reliable. The reason is that reported earnings can be manipulated easily by adjusting any numbers such as Depreciation, Depletion and Amotorization and non-recurring items.
But the long term trend of the net margin is a good indicator of the competitiveness and health of the business.
Grifols Net Margin % Related Terms
Grifols Net Margin % Historical Data
* Premium members only.
The historical data trend for Grifols's Net Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
MEX:GRFP N vs LLY, JNJ, ABBV: Net Margin % Comparison
For the Drug Manufacturers - General subindustry, Grifols's Net Margin %, along with its competitors' market caps and Net Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Grifols Net Margin % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Grifols's Net Margin % distribution charts can be found below:
* The bar in red indicates where Grifols's Net Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Grifols (MEX:GRFP N) has a Net Margin % of 4.29% as of Mar. 2026. Net margin is the ratio of total net income to net sales. View historical data on Grifols and its competitors. This is 49% below median its historical median of 8.46. Over the past decade, Grifols' Net Margin % has ranged from 0.64 to 15.35. According to the industry distribution chart, Grifols ranks #478 out of 956 companies in the Drug Manufacturers industry, placing it in the top 50%.
Is Grifols' Net Margin % too high?
Grifols' current Net Margin % of 4.29% is 49% below median its 10-year median of 8.46. Over the past 10 years, this metric has ranged from a low of 0.64 to a high of 15.35. The Drug Manufacturers industry median Net Margin % is 5.56. Grifols' value of 4.29% is 22.8% below this industry median. Based on the distribution chart, Grifols ranks #478 out of 956 companies in the Drug Manufacturers industry, which is above the industry midpoint. Overall, Grifols has a GF Score™ of 83/100, reflecting its overall financial health beyond just this single metric.
How does Grifols' Net Margin % compare to LLY and JNJ?
According to the Drug Manufacturers industry distribution chart, Grifols ranks #478 out of 956 companies for Net Margin %. This puts Grifols in the upper half of its industry. The industry median Net Margin % is 5.56. Grifols' value of 4.29% is 22.8% below this benchmark. Historically, Grifols' own Net Margin % has ranged from 0.64 to 15.35 over the past decade. While the company's 10-year median is 8.46 vs. the industry median of 5.56, Grifols has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Net Margin % for a Drug Manufacturers company?
The median Net Margin % among Drug Manufacturers companies is 5.56, based on 956 companies in the industry. Companies in the top quartile (top 25%) have a Net Margin % significantly above this median, while those in the bottom quartile fall well below. However, Net Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Grifols's current Net Margin % of 4.29% is 22.8% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Net Margin % mean?
A high Net Margin % can signal that a stock is expensive relative to its fundamentals. Net margin is the ratio of total net income to net sales. View historical data on Grifols and its competitors. For the Drug Manufacturers industry, the median Net Margin % is 5.56 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Grifols's current Net Margin % is 4.29%, which is 49% below median its own 10-year median of 8.46. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Grifols stock overvalued right now?
Grifols (MEX:GRFP N) has a current Net Margin % of 4.29%. The stock's GF Value™ is MXN154.24, compared to a current price of MXN126.63 — trading 17.9% below its estimated fair value. The current Net Margin % is 4.29%, which is 49% below median its 10-year median of 8.46 and 22.8% below the Drug Manufacturers industry median of 5.56. Grifols' overall GF Score™ is 83/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Net Margin % calculated?
Net Margin % is calculated from a company's financial statements. For Grifols (MEX:GRFP N), the current Net Margin % is 4.29% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Grifols (MEX:GRFP N) Overvalued in 2026?
Based on GuruFocus' analysis, Grifols stock appears to be undervalued.
The current stock price of MXN126.63 is trading 17.9% below its estimated GF Value™ of MXN154.24.
Key valuation signals for MEX:GRFP N:
Net Margin %: 4.29% (49% below median its 10-year median of 8.46)
GF Value™: MXN154.24 vs. price of MXN126.63 (17.9% below fair value)
Industry Position: 22.8% below the Drug Manufacturers median (#478 of 956)
No single metric tells the full story. See the MEX:GRFP N stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Grifols SA is a healthcare company engaged in activities related to plasma-derived products and diagnostic solutions. The group has four reportable segments: Biopharma, Diagnostic, Bio Supplies, and Others. The Biopharma segment focuses on products derived from human plasma for therapeutic use, while the Diagnostic segment includes the marketing of diagnostic testing equipment and reagents. The Bio Supplies segment covers biological products for non-therapeutic use and plasma sales to third parties, and the Others segment includes manufacturing services, research activities, and complementary pharmaceutical products.
83GF Score
Get the complete analysis for MEX:GRFP N
Net Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
MEX:GRFP N has been successfully added to your 
